Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Peng-Fei Zhang, Dan Xie, Qiu Li
Формат:	Өгүүллэг
Хэл сонгох:	English
Хэвлэсэн:	Frontiers Media S.A. 2021-02-01
Цуврал:	Frontiers in Public Health
Нөхцлүүд:	prostate cancer enzalutamide cost-effectiveness androgen deprivation therapy first-line
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full

Ижил төстэй зүйлс

Choice of treatment options for metastatic hormone-sensitive prostate cancer
-н: R. A. Gafanov, зэрэг
Хэвлэсэн: (2020-12-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
-н: Onur Baser, зэрэг
Хэвлэсэн: (2024-04-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
-н: Chi-Shin Tseng, зэрэг
Хэвлэсэн: (2023-06-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
-н: B. Ya. Alekseyev, зэрэг
Хэвлэсэн: (2019-12-01)

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
-н: Francesca Fiorentino, зэрэг
Хэвлэсэн: (2023-04-01)

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
-н: Thomson A, зэрэг
Хэвлэсэн: (2024-10-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
-н: Kouji Izumi, зэрэг
Хэвлэсэн: (2022-07-01)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
-н: Günel Huseynova, зэрэг
Хэвлэсэн: (2022-12-01)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
-н: Alexandra Vander Ark, зэрэг
Хэвлэсэн: (2018-05-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
-н: Namrata Khurana, зэрэг
Хэвлэсэн: (2020-01-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
-н: Ahmet Dirican, зэрэг
Хэвлэсэн: (2022-11-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
-н: Jukapun Yoodee, зэрэг
Хэвлэсэн: (2022-11-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
-н: T. V. Ustinova, зэрэг
Хэвлэсэн: (2021-12-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
-н: Jo-Lynn Tan, зэрэг
Хэвлэсэн: (2017-12-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
-н: Kouji Izumi, зэрэг
Хэвлэсэн: (2017-10-01)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
-н: Hui-Ming Lin, зэрэг
Хэвлэсэн: (2021-10-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
-н: Pedro Cardoso, зэрэг
Хэвлэсэн: (2020-05-01)

Practical implications of androgen receptor inhibitors for prostate cancer treatment
-н: Fabio Campodonico, зэрэг
Хэвлэсэн: (2024-05-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
-н: Sung Hee Lim, зэрэг
Хэвлэсэн: (2024-03-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
-н: Timothy C. Wright, зэрэг
Хэвлэсэн: (2021-07-01)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
-н: Anders Bjartell, зэрэг
Хэвлэсэн: (2022-11-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
-н: Zhe Zhu, зэрэг
Хэвлэсэн: (2024-11-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
-н: Marcus Moses, MS, зэрэг
Хэвлэсэн: (2020-01-01)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
-н: Pravien Rajaram, зэрэг
Хэвлэсэн: (2020-05-01)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
-н: Ralph E. White, зэрэг
Хэвлэсэн: (2023-06-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
-н: Stefanie Fischer, зэрэг
Хэвлэсэн: (2020-01-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
-н: Xiangyun You, зэрэг
Хэвлэсэн: (2023-04-01)

MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
-н: Shengfeng Zheng, зэрэг
Хэвлэсэн: (2024-10-01)

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer
-н: Rosanne CV. Van der Roest, зэрэг
Хэвлэсэн: (2016-07-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
-н: Nair Lopes, зэрэг
Хэвлэсэн: (2021-08-01)

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
-н: Xiaohong Xia, зэрэг
Хэвлэсэн: (2019-05-01)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
-н: Mikio Sugimoto, зэрэг
Хэвлэсэн: (2022-09-01)

Role of Androgen Receptor-Targeted Agents in Localized Prostate Cancer
-н: Jure Murgić, зэрэг
Хэвлэсэн: (2022-01-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
-н: Saizo Fujmoto, зэрэг
Хэвлэсэн: (2023-02-01)

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
-н: Zhu Wen, зэрэг
Хэвлэсэн: (2024-08-01)

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
-н: Borui Kang, зэрэг
Хэвлэсэн: (2023-05-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
-н: N. A. Avxentyev, зэрэг
Хэвлэсэн: (2019-01-01)

Recent progress and controversies in the treatment of metastatic hormone-sensitive prostate cancer
-н: Wei-hua Liu, зэрэг
Хэвлэсэн: (2024-06-01)

New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide
-н: Sergey A. Dyshlovoy, зэрэг
Хэвлэсэн: (2023-01-01)

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer
-н: Yang Chen, зэрэг
Хэвлэсэн: (2022-12-01)